XML 72 R63.htm IDEA: XBRL DOCUMENT v3.24.3
Warrants - Additional Information (Details) - USD ($)
1 Months Ended 9 Months Ended
Dec. 31, 2023
Sep. 29, 2023
Jun. 30, 2023
Mar. 21, 2023
Dec. 31, 2022
Sep. 30, 2024
Nov. 30, 2023
Nov. 21, 2023
Oct. 03, 2023
Class of Warrant or Right [Line Items]                  
Warrants and rights outstanding, term (year) 2 years 9 months 21 days         2 years 21 days     5 years
PIPE Private Placement Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Class of warrant or right, exercise price of warrants or rights (in dollars per share)         $ 10.8 $ 10.8      
Warrants Issued         736,337 736,337      
Placement Agent Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Class of warrant or right, exercise price of warrants or rights (in dollars per share)         $ 13.5 $ 13.5      
Warrants Issued         21,091 21,091      
Warrants and rights outstanding, term (year)         5 years        
Warrants or right, issued, percentage of shares purchased         7.00%        
Ladenburg Agreement Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Class of warrant or right, exercise price of warrants or rights (in dollars per share)       $ 5.424   $ 5.424      
Stock issued during period, shares, new issues (in shares)     191,689            
Warrants Issued       30,000          
Warrants and rights outstanding, term (year)       3 years          
Stock issued $ 1,100,000   $ 1,500,000 $ 500,000          
Cash payment to settle warrants           $ 1,100,000      
Warrants and rights outstanding, fair value per share (in dollars per share)           $ 3.1      
Warrants, value           $ 93,000      
Preferred Tranche B Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Warrants and rights outstanding, term (year) [1] 8 months 8 days         5 months 12 days      
Outstanding warrants 42,846         42,846      
Preferred Tranche C Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Warrants and rights outstanding, term (year) [2] 4 years 10 months 28 days         4 years 1 month 28 days      
Outstanding warrants 107,115         107,115      
Preferred PIPE Placement Agent Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Class of warrant or right, exercise price of warrants or rights (in dollars per share)               $ 6.3  
Warrants Issued               850,119  
Outstanding warrants 850,119         850,119      
Preferred Placement Agent Warrant [Member]                  
Class of Warrant or Right [Line Items]                  
Class of warrant or right, exercise price of warrants or rights (in dollars per share)             $ 6.3    
Warrants and rights outstanding, fair value per share (in dollars per share)           $ 4.4      
Preferred Placement Agent Warrant [Member] | Additional Paid-In Capital [Member]                  
Class of Warrant or Right [Line Items]                  
Warrants, value           $ 3,700,000      
Private Placement [Member]                  
Class of Warrant or Right [Line Items]                  
Stock issued during period, shares, new issues (in shares)         736,337        
Equity offering, combined purchase price (in dollars per share)         $ 10.8        
Equity offering, premium per share (in dollars per share)         $ 1.25        
Warrants and rights outstanding, term (year)         5 years        
Placement agent fee, percentage of gross proceeds         7.00%        
Proceeds from issuance or sale of equity         $ 8,000,000        
Private Placement [Member] | Preferred Tranche B Warrants [Member] | Securities Purchase Agreement [Member]                  
Class of Warrant or Right [Line Items]                  
Aggregate exercise price   $ 52,000,000              
Private Placement [Member] | Preferred Tranche B Warrants [Member] | Securities Purchase Agreement [Member] | Series A-3 Preferred Stock [Member]                  
Class of Warrant or Right [Line Items]                  
Outstanding warrants           42,846      
Aggregate exercise price           $ 42,850,000      
Private Placement [Member] | Preferred Tranche C Warrants [Member] | Securities Purchase Agreement [Member]                  
Class of Warrant or Right [Line Items]                  
Aggregate exercise price   $ 130              
Private Placement [Member] | Preferred Tranche C Warrants [Member] | Securities Purchase Agreement [Member] | Series A-3 Preferred Stock [Member]                  
Class of Warrant or Right [Line Items]                  
Outstanding warrants           107,115      
Aggregate exercise price           $ 107,100,000      
Public Warrants [Member]                  
Class of Warrant or Right [Line Items]                  
Class of warrant or right, number of securities called by each warrant or right (in shares)           1      
Class of warrant or right, exercise price of warrants or rights (in dollars per share)           $ 115      
Warrants or rights, redemption price (in dollars per share)           0.01      
Warrants and rights outstanding, minimum share price to call (in dollars per share)           $ 180      
[1] Reflects a probability-weighted input derived from multiple Black-Scholes calculations, which take into account the various potential dates for the announcement of the SAB-142-101 data. This probability was estimated to be 45.0% as of December 31, 2023, and further reduced to 10.0% as of September 30, 2024. This adjustment was driven by progress around enrollment for the ongoing clinical trial.
[2] Reflects a probability-weighted input derived from multiple Black-Scholes calculations. These calculations incorporate the Company’s estimated probability of dissolution, should SABS’ intellectual property fail to yield positive results in forthcoming clinical trials, potentially leading to dissolution before 2028. The probability was 38.5% and 25.0% as of September 30, 2024 and December 31, 2023, respectively.